Conflict of interest
CNL
Penn State Research Foundation has licensed Ceramide nanoLiposomes (CNL) to Keystone Nano (KN) Inc. KN, who holds the IND for the phase I clinical trial, is developing CNL as Ceraxa™. Jeff Davidson is Chief Operating Officer of KN and Mylisa Parette previously served as Vice President of Research at KN. There are no other financial or non-financial conflicts of interest directly or indirectly related to this manuscript.